From the Wires
Novo Nordisk A/S: Ryzodeg(R) (insulin degludec/insulin aspart) passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan
Dec. 3, 2012 01:49 AM
BAGSVAERD, DENMARK -- (Marketwire) -- 12/03/12 --
Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin
aspart) has passed the review by the First Committee on Drugs of Japan's
Pharmaceutical Affairs. The remaining step in the regulatory process is an
approval from the Ministry of Health, Labour and Welfare.
Company announcement No 78 / 2012:
http://hugin.info/2013/R/1661613/538373.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1661613]
About Marketwire .Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
.gif)
